EP0757558A4 - Procedes de criblage des agents modulateurs des inflammations tegumentaires - Google Patents

Procedes de criblage des agents modulateurs des inflammations tegumentaires

Info

Publication number
EP0757558A4
EP0757558A4 EP95917009A EP95917009A EP0757558A4 EP 0757558 A4 EP0757558 A4 EP 0757558A4 EP 95917009 A EP95917009 A EP 95917009A EP 95917009 A EP95917009 A EP 95917009A EP 0757558 A4 EP0757558 A4 EP 0757558A4
Authority
EP
European Patent Office
Prior art keywords
integumental
screening methods
modulating agents
inflammation modulating
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95917009A
Other languages
German (de)
English (en)
Other versions
EP0757558A1 (fr
Inventor
Vivien Mak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adolor Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Priority to EP99201333A priority Critical patent/EP0937460A3/fr
Publication of EP0757558A1 publication Critical patent/EP0757558A1/fr
Publication of EP0757558A4 publication Critical patent/EP0757558A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
EP95917009A 1994-04-12 1995-04-11 Procedes de criblage des agents modulateurs des inflammations tegumentaires Withdrawn EP0757558A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP99201333A EP0937460A3 (fr) 1994-04-12 1995-04-11 Utilisation d'un antidiarrhéique pour la préparation d'un médicament pour le traitement des inflammations

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US22599194A 1994-04-12 1994-04-12
US225991 1994-04-12
US27128794A 1994-07-06 1994-07-06
US271287 1994-07-06
US40023495A 1995-03-03 1995-03-03
US400234 1995-03-03
PCT/US1995/004677 WO1995027510A1 (fr) 1994-04-12 1995-04-11 Procedes de criblage des agents modulateurs des inflammations tegumentaires

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP99201333A Division EP0937460A3 (fr) 1994-04-12 1995-04-11 Utilisation d'un antidiarrhéique pour la préparation d'un médicament pour le traitement des inflammations

Publications (2)

Publication Number Publication Date
EP0757558A1 EP0757558A1 (fr) 1997-02-12
EP0757558A4 true EP0757558A4 (fr) 1999-06-16

Family

ID=27397548

Family Applications (2)

Application Number Title Priority Date Filing Date
EP95917009A Withdrawn EP0757558A4 (fr) 1994-04-12 1995-04-11 Procedes de criblage des agents modulateurs des inflammations tegumentaires
EP99201333A Withdrawn EP0937460A3 (fr) 1994-04-12 1995-04-11 Utilisation d'un antidiarrhéique pour la préparation d'un médicament pour le traitement des inflammations

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP99201333A Withdrawn EP0937460A3 (fr) 1994-04-12 1995-04-11 Utilisation d'un antidiarrhéique pour la préparation d'un médicament pour le traitement des inflammations

Country Status (4)

Country Link
EP (2) EP0757558A4 (fr)
JP (1) JPH10500669A (fr)
AU (1) AU2385795A (fr)
WO (1) WO1995027510A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0754046A1 (fr) * 1994-04-04 1997-01-22 FREEMAN, William R. Emploi de nucleosides de phosphonylemethoxyalkyle pour traiter la pression intra-oculaire elevee
KR100455006B1 (ko) 1995-12-21 2005-01-13 소시에떼 데 프로듀이 네슬레 소시에떼아노님 향상된불사화사람피부세포계및이의제조에유용한신규한무혈청배지
US5798093A (en) * 1997-03-14 1998-08-25 Adolor Corporation Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions and pruritus therewith
US5849762A (en) * 1997-07-14 1998-12-15 Adolor Corporation Peripherally acting anti-pruritic opiates
US6353004B1 (en) 1997-07-14 2002-03-05 Adolor Coporation Peripherally acting anti-pruritic opiates
AUPP646498A0 (en) 1998-10-12 1998-11-05 Australian National University, The A method of modulating ion channel functional activity
DE19948126A1 (de) * 1999-10-06 2001-04-12 Max Delbrueck Centrum Pharmazeutisches Mittel zur Behandlung von Kachexie und/oder kardiogenem Schock
CA2416152A1 (fr) * 2000-07-27 2002-02-07 Pharmacia Corporation Therapie anti-aldosterones destinee a prevenir ou traiter les troubles lies a une inflammation
US6697668B2 (en) * 2001-01-25 2004-02-24 Iomed, Inc. Ocular iontophoretic device and method for using the same
KR20040078683A (ko) * 2002-01-30 2004-09-10 파마시아 코포레이션 심혈관 질환의 예방 또는 치료를 위한 알도스테론 길항제및 비스테로이드 소염제의 조합 치료법
ZA200804907B (en) * 2004-08-18 2009-04-29 Ace Aps Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists
EP2043650A2 (fr) * 2006-07-14 2009-04-08 Medical Research Council Traitement d'une maladie démyélinisante
JP2008222603A (ja) * 2007-03-09 2008-09-25 Institute Of Physical & Chemical Research 神経変性疾患の予防・治療剤
JP2022531154A (ja) * 2019-04-30 2022-07-06 ジェネロス バイオファーマ リミテッド 炎症により引き起こされる自己免疫性皮膚疾患を治療するための化合物及びその使用
WO2022253910A1 (fr) * 2021-06-02 2022-12-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouveau procédé pour traiter une maladie cutanée inflammatoire

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002497A1 (fr) * 1989-08-21 1991-03-07 Beth Israel Hospital Association Nifedipine topique pour le traitement de l'hypersensibilite cutanee, oculaire et de la muqueuse, ainsi que d'etats inflammatoires et hyperproliferatifs
DD297062A5 (de) * 1990-08-23 1992-01-02 Tks Optimum Gmbh,Dd Verfahren zur herstellung eines neuartigen topischen dermatikums mit antientzuendlicher wirkung
US5202130A (en) * 1989-08-31 1993-04-13 The Johns Hopkins University Suppression of eczematous dermatitis by calcium transport inhibition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4384000A (en) * 1980-08-07 1983-05-17 Lanier Earl W Method for treatment of various dermatological conditions
GB8806224D0 (en) * 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
US5116847A (en) * 1991-01-25 1992-05-26 The Procter & Gamble Company Use of loperamide and related compounds for treatment of respiratory disease symptoms

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002497A1 (fr) * 1989-08-21 1991-03-07 Beth Israel Hospital Association Nifedipine topique pour le traitement de l'hypersensibilite cutanee, oculaire et de la muqueuse, ainsi que d'etats inflammatoires et hyperproliferatifs
US5202130A (en) * 1989-08-31 1993-04-13 The Johns Hopkins University Suppression of eczematous dermatitis by calcium transport inhibition
DD297062A5 (de) * 1990-08-23 1992-01-02 Tks Optimum Gmbh,Dd Verfahren zur herstellung eines neuartigen topischen dermatikums mit antientzuendlicher wirkung

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EVANS CH ET AL.: "Inhibition, by lanthanides, of neutral proteinases secreted by human rheumatoid synovium", EUR.J.BIOCHEM., vol. 151, 1985, pages 29 - 32, XP002098132 *
GANGAROSA L P ET AL: "CONDUCTIVITY OF DRUGS USED FOR IONTOPHORESIS", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 67, no. 10, October 1978 (1978-10-01), pages 1439 - 1443, XP002055803 *
J.INVESTIG.DERMATOL., vol. 93, no. 3, 1989, pages 322 - 326, XP002098133 *
See also references of WO9527510A1 *

Also Published As

Publication number Publication date
EP0757558A1 (fr) 1997-02-12
AU2385795A (en) 1995-10-30
JPH10500669A (ja) 1998-01-20
EP0937460A3 (fr) 2000-04-05
EP0937460A2 (fr) 1999-08-25
WO1995027510A1 (fr) 1995-10-19

Similar Documents

Publication Publication Date Title
EP0757558A4 (fr) Procedes de criblage des agents modulateurs des inflammations tegumentaires
IL117886A (en) Switched-inverter modulator
GB9425275D0 (en) Road apparatus
ZA95701B (en) Rivets-nails and methods for their implementation
GB9705893D0 (en) Holographic screen
GB9409128D0 (en) Anticounterfeit apparatus
GR3030985T3 (en) Freezing apparatus
DE69601083D1 (en) Passiver akusto-optischer modulator
EP0703422A3 (fr) Appareil de congélation
KR100202287B1 (en) Disc apparatus
GB9426197D0 (en) Closure apparatus
GB2329287B (en) Closure apparatus
GB9403375D0 (en) Hydraulic apparatus
GB9408659D0 (en) Hinge
GB2320149B (en) Modulators
GB2295201B (en) Hinge
GB9414902D0 (en) Methods
PL306105A1 (en) Electrooptical modulator
GB2290827B (en) Hinges
GB9400830D0 (en) Fixing method
PL305029A1 (en) Lorry
GB9413676D0 (en) Hydraulic apparatus
GB9423560D0 (en) Shearing apparatus
IL110441A0 (en) Fungicides and method for using same
GB9401066D0 (en) An applicator

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19961111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ADOLOR CORPORATION

A4 Supplementary search report drawn up and despatched

Effective date: 19990507

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19990929

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000411

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1014501

Country of ref document: HK